Answers are grounded in this paper and cite their sources.
The Diagnosis Confirmation Model (DCM) includes a dual-pricing mechanism designed to support value-based pricing of novel antibiotics while improving the alignment of financial incentives with their optimal use in patients at high risk of drug-resistant infections. DCM is a market-based model and complementary to delinked models. Policymakers interested in stimulating antibiotic innovation could consider tailoring the DCM to their reimbursement systems and incorporating it into the suite of incentives to improve the economics of antibiotics.
No takes yet. Share an insight, caveat, or question.
Lum et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: